Pharmaceuticals

Valeant Pharmaceuticals International (NYSE: VRX), announced today that it has agreed to acquire Afexa Life Sciences Inc. for approximately C$76 million. Afexa, a health-science company headquartered in Edmonton, Alberta, Canada, currently markets several consumer brands, such as COLD-FX® and...

Perrigo Company (Nasdaq: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina® Ketoconazole Foam, 2%. Perrigo has commenced shipping of the product and...

Pre-open movers US stock futures are lower this morning, as investors are awaiting consumer confidence data and the minutes of the recent Federal Open Market Committee. Futures for the Dow Jones Industrial Average dipped 49 points to 11,468.00 and S&P 500 index futures fell 6.30 points to 1,201...

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the U.S. Food and Drug Administration has accepted for filing a supplemental New Drug Application for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection to treat opioid-induced...

ICON plc, (NASDAQ: ICLR) today announced that it has been chosen by Bristol-Myers Squibb Company (NYSE: BMY) as a preferred provider for full-service clinical pharmacology and exploratory clinical studies. This latest agreement with Bristol-Myers-Squibb follows the company's selection of ICON to...

Teva Pharmaceuticals (NASDAQ: TEVA) has been in the courtroom multiple times over generic drugs. In the past, they have been on the defensive, trying to protect their generic versions of Pfizer's drugs. Recently, Teva has been on the offensive, trying to protect its multiple sclerosis drug from...

Pfizer Inc. (NYSE: PFE) has received FDA approval of XALKORI® (crizotinib) capsules – the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase ALK-positive as detected by an FDA-approved test. The...

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the Southern District of New York has issued a favorable set of claim construction rulings in the Company's patent infringement lawsuit against Sandoz Inc./Momenta Pharmaceuticals, Inc. and Mylan/...

J.P. Morgan is out with its report today on Bristol-Myers Squibb (NYSE: BMY), maintaining Neutral. In its report, J.P. Morgan writes, "We continue to view pipeline progression as the key driver for BMY shares in 2011 and view the company as having the best pipeline relative to its size in the...

J.P. Morgan is out with its report today on Pfizer (NYSE: PFE), maintaining Overweight. In its report, J.P. Morgan writes, "We believe Pfizer's strategic view has helped refocus the Street on the value of the various business units within Pfizer even though the outcome of the process (seeking...

Icagen (NASDAQ: ICGN) announced today that it has sent the following letter to stockholders affirming the Board's recommendation after receiving a letter from Pfizer (NYSE: PFE) on Friday, August 26, 2011 stating that Pfizer's best and final offer price is $6.00 per share:

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced today that its Board of Directors has approved an increase of $300 million under its previously announced securities repurchase program. Under the Securities Repurchase Program, Valeant may now repurchase up to $1.8 billion of its...

Piper Jaffray is out with its report today on Endo Pharmaceuticals (NASDAQ: ENDP), reiterating Overweight. In its report, Piper Jaffray writes, "We believe that ENDP shares are valued attractively at trough annual operating cash flows (i.e., inclusive of the impact of generics on Opana ER and...

Bank of America has raised the price objective on Bristol-Myers Squibb (NYSE: BMY) from $31 to $32 and maintains its Neutral rating.

The U.S. Food and Drug Administration today approved Pfizer's (NYSE: PFE) Xalkori to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase gene. Xalkori is being approved with a companion diagnostic...